Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
3
60%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Other(1)

Detailed Status

Completed3
Not yet recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

not_yet_recruiting120%
unknown120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
not_yet_recruiting

GLP1 Analogues and the Risk of Osteoarthritis

NCT07360457
unknownphase_2

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

NCT05565976
completedphase_2

Magnesium Supplementation in Diabetic Nephropathy

NCT03824379
completed

Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study

NCT04375943
completedphase_2

Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

NCT03850886

Clinical Trials (5)

Showing 5 of 5 trials
NCT07360457

GLP1 Analogues and the Risk of Osteoarthritis

Not Yet Recruiting
NCT05565976Phase 2

Dapagliflozin Effect in Cognitive Impairment in Stroke Trial

Unknown
NCT03824379Phase 2

Magnesium Supplementation in Diabetic Nephropathy

Completed
NCT04375943

Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study

Completed
NCT03850886Phase 2

Nicotinamide in Non-Alcoholic Fatty Liver Disease Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5